125 related articles for article (PubMed ID: 1756257)
1. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67.
Weikel W; Beck T; Mitze M; Knapstein PG
Breast Cancer Res Treat; 1991 Aug; 18(3):149-54. PubMed ID: 1756257
[TBL] [Abstract][Full Text] [Related]
2. [The immunohistochemical growth fraction (Ki-67) of breast cancers: relations to tumor spread, tumor morphology and receptor testing].
Weikel W; Beck T; Rosenthal H; Herzog R
Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):277-82. PubMed ID: 2566552
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study.
Wrba F; Chott A; Reiner A; Reiner G; Markis-Ritzinger E; Holzner JH
Oncology; 1989; 46(4):255-9. PubMed ID: 2662089
[TBL] [Abstract][Full Text] [Related]
4. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer.
Rudolph P; Alm P; Heidebrecht HJ; Bolte H; Ratjen V; Baldetorp B; Fernö M; Olsson H; Parwaresch R
J Natl Cancer Inst; 1999 Feb; 91(3):271-8. PubMed ID: 10037106
[TBL] [Abstract][Full Text] [Related]
5. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1.
Keshgegian AA; Cnaan A
Am J Clin Pathol; 1995 Jul; 104(1):42-9. PubMed ID: 7611179
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
[TBL] [Abstract][Full Text] [Related]
7. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors.
Weikel W; Brumm C; Wilkens C; Beck T; Knapstein PG
Cancer Detect Prev; 1995; 19(5):446-50. PubMed ID: 7585732
[TBL] [Abstract][Full Text] [Related]
8. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences.
Gaglia P; Bernardi A; Venesio T; Caldarola B; Lauro D; Cappa AP; Calderini P; Liscia DS
Eur J Cancer; 1993; 29A(11):1509-13. PubMed ID: 8217353
[TBL] [Abstract][Full Text] [Related]
9. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
[TBL] [Abstract][Full Text] [Related]
12. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
14. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma.
Lee AK; Wiley B; Loda M; Bosari S; Dugan JM; Hamilton W; Heatley GJ; Cook L; Silverman ML
Mod Pathol; 1992 Jan; 5(1):61-7. PubMed ID: 1347424
[TBL] [Abstract][Full Text] [Related]
15. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
Thor AD; Schwartz LH; Koerner FC; Edgerton SM; Skates SJ; Yin S; McKenzie SJ; Panicali DL; Marks PJ; Fingert HJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7147-52. PubMed ID: 2573426
[TBL] [Abstract][Full Text] [Related]
16. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.
Gerdes J; Lelle RJ; Pickartz H; Heidenreich W; Schwarting R; Kurtsiefer L; Stauch G; Stein H
J Clin Pathol; 1986 Sep; 39(9):977-80. PubMed ID: 3020096
[TBL] [Abstract][Full Text] [Related]
17. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
18. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis.
Ceriani RL; Chan CM; Baratta FS; Ozzello L; DeRosa CM; Habif DV
Int J Cancer; 1992 May; 51(3):343-54. PubMed ID: 1592525
[TBL] [Abstract][Full Text] [Related]
19. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
20. Multicentric mammary carcinoma: evidence of monoclonal proliferation.
Middleton LP; Vlastos G; Mirza NQ; Eva S; Sahin AA
Cancer; 2002 Apr; 94(7):1910-6. PubMed ID: 11932891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
